When Novartis bought a 25 percent stake in Alcon from its parent company, Nestlé, it reserved the right to buy the remaining shares for a fixed price between Jan. 1, 2010, and July 31, 2011. However, Novartis' chief financial officer, Meryl Zausner, has told the Financial Times that the company ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.